MedPath

Investigation of the effect of oral L-arginine on pulmonary hypertension in patients with thalassemia major

Phase 3
Conditions
Beta thalassemia.
Registration Number
IRCT20191218045785N1
Lead Sponsor
Shahre-kord University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Major or intermedia thalassemia with PAP> 30
Systemic blood pressure over 60/90

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pulmonary arterial pressure. Timepoint: Baseline (before intervention) and 6 and 30 days after L-arginine administration. Method of measurement: Echocardiography.
Secondary Outcome Measures
NameTimeMethod
Systemic blood pressure. Timepoint: Baseline (before intervention) and 6 and 30 days after L-arginine administration. Method of measurement: Blood pressure monitor.
© Copyright 2025. All Rights Reserved by MedPath